GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (CHIX:OXBl) » Definitions » EV-to-EBITDA

Oxford BioMedica (CHIX:OXBL) EV-to-EBITDA : -26.65 (As of Jun. 25, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Oxford BioMedica EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oxford BioMedica's enterprise value is £382.0 Mil. Oxford BioMedica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was £-14.3 Mil. Therefore, Oxford BioMedica's EV-to-EBITDA for today is -26.65.

The historical rank and industry rank for Oxford BioMedica's EV-to-EBITDA or its related term are showing as below:

CHIX:OXBl' s EV-to-EBITDA Range Over the Past 10 Years
Min: -75.07   Med: -5.16   Max: 316.32
Current: -26.65

During the past 13 years, the highest EV-to-EBITDA of Oxford BioMedica was 316.32. The lowest was -75.07. And the median was -5.16.

CHIX:OXBl's EV-to-EBITDA is ranked worse than
100% of 489 companies
in the Biotechnology industry
Industry Median: 8.47 vs CHIX:OXBl: -26.65

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-25), Oxford BioMedica's stock price is £3.095. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was £-0.418. Therefore, Oxford BioMedica's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Oxford BioMedica EV-to-EBITDA Historical Data

The historical data trend for Oxford BioMedica's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica EV-to-EBITDA Chart

Oxford BioMedica Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.97 28.90 -39.63 -1.51 -34.65

Oxford BioMedica Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.63 - -1.51 - -34.65

Competitive Comparison of Oxford BioMedica's EV-to-EBITDA

For the Biotechnology subindustry, Oxford BioMedica's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's EV-to-EBITDA falls into.


;
;

Oxford BioMedica EV-to-EBITDA Calculation

Oxford BioMedica's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=382.029/-14.333
=-26.65

Oxford BioMedica's current Enterprise Value is £382.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was £-14.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica  (CHIX:OXBl) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Oxford BioMedica's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.095/-0.418
=At Loss

Oxford BioMedica's share price for today is £3.095.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was £-0.418.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Oxford BioMedica EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types.

Oxford BioMedica Headlines

No Headlines